Differences in the treatment of exudative age-related macular degeneration in Germany and Great Britain;Unterschiede in der Therapie der exsudativen altersabhängigen Makuladegeneration in Deutschland und Großbritannien

Ophthalmologe

Volumn 108, Issue 6, 2011, Pages 575-584

  Heimann, H ^a   Yang, Y ^b   Wachtlin, J ^c   Pauleikhoff, D ^d  

^a ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

^b Wolverhampton and Midland Counties Eye Infirmary   (United Kingdom)

^c Sankt Gertrauden Krankenhaus   (Germany)

^d ST FRANZISKUS HOSPITAL   (Germany)

Author keywords

Age related macular degeneration; Bevacizumab; Germany; Great Britain; Ranibizumab

Indexed keywords

APTAMER; BEVACIZUMAB; MONOCLONAL ANTIBODY; PEGAPTANIB; RANIBIZUMAB; VASCULOTROPIN A;

ARTICLE; COMPARATIVE STUDY; CULTURAL FACTOR; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG ANTAGONISM; DRUG COST; ECONOMICS; EXUDATIVE MACULAR DEGENERATION; GERMANY; HEALTH CARE COST; HUMAN; INTRAVITREAL DRUG ADMINISTRATION; NATIONAL HEALTH SERVICE; PRACTICE GUIDELINE; PUBLIC HEALTH; STATISTICS; UNITED KINGDOM;

ANTIBODIES, MONOCLONAL, HUMANIZED; APTAMERS, NUCLEOTIDE; CROSS-CULTURAL COMPARISON; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG COSTS; GERMANY; GREAT BRITAIN; GUIDELINE ADHERENCE; HEALTH CARE COSTS; HEALTH EXPENDITURES; HUMANS; INTRAVITREAL INJECTIONS; NATIONAL HEALTH PROGRAMS; STATE MEDICINE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; WET MACULAR DEGENERATION;

EID: 79959358439     PISSN: 0941293X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00347-011-2383-0     Document Type: Article

References (22)

1. Europe in figures. Eurostat yearbook 2010. http://www. epp. eurostat. ec. europa. eu/portal/page/portal/product_details/publication?p_product_code=KS-CD-10-220.
2. European Medicines Agency. http://www. ema. europa. eu/ema/index. jsp?curl=pages/medicines/human/medicines/000715/human_med_000890. jsp& murl=menus/medicines/medicines. jsp& mid=WC0b0lac05800ldl24& jsenabled=true.
3. European Union of Medical Specialists. http://www. admin. uems. net/uplpoadfiles/1316. pdf.
4. International Monetary Fund. Principal global indicators. http://www. principalglobalindicatorsorg/default. aspx.
5. National Institute for Health and Clinical Excellence: Macular degeneration (age-related) - ranibizumab and pegaptanib. http://www. guidance. nice. org. uk/TA155.
6. Aktuelle Stellungnahme der Retinologischen Gesellschaft, der Deutschen Ophthalmologischen Gesellschaft und des Berufsverbands der Augenärzte Deutschlands e. V. (2009) Neue Aspekte in der Therapie der neovaskulären altersabhängigen Makuladegeneration. Ophthalmologe 106: 457-464.
7. Neue Aspekte in der Therapie der neovaskulären altersabhängigen Makuladegeneration: Kriterien der Wiederbehandlung bei der Anti-VEGF Therapie (2010). www. dog. org/wp-content/uploads/2009/09/Stellungnahme-AMD-Ergänzung-010411. pdf.
8. Amoaku W (2009) Ranibizumab: the clinician's guide to commencing, continuing, and discontinuing treatment. Eye 23: 2140-2142.
9. Aktualisiertes Konsenspapier der Retinologischen Gesellschaft, der Deutschen Ophthalmologischen Gesellschaft und des Berufsverbands der Augenärzte (2006) Stellungnahme zu aktuellen therapeutischen Möglichkeiten bei der neovaskulären altersabhängigen Makuladegeneration. Ophthalmologe 103: 447-452.
10. Konsenspapier der Retinologischen Gesellschaft, der Deutschen Ophthalmologischen Gesellschaft und des Berufsverbandes der Augenärzte (2005) Stellungnahme zur aktuellen Therapie der neovaskulären AMD. Ophthalmologe 102: 545-558.
11. Busse R (2006) Europäische Gesundheitssysteme - Grundfragen und Vergleich. Volkswirtschaft 12: 10-13.
12. Guerin M, Flynn T, Brady J et al (2008) Worldwide geographical distribution of ophthalmology publications. Int Ophthalmol [Epub ahead of print].
13. Heimes B, Lommatzsch A, Zeimer M et al (2011) Long-term visual course after anti-VEGF therapy for exudative AMD in clinical practice evaluation of the German reinjection scheme. Graefes Arch Clin Exp Ophthalmol 249: 639-644.
14. Kumar A, Sahni J, Stangos AN et al (2011) Effectiveness of ranibizumab for neovascular age-related macular degeneration using clinician-determined retreatment strategy. Br J Ophthalmol 95: 530-533.
15. Lotery A, Xu X, Zlatava G et al (2007) Burden of illness, visual impairment and health resource utilisation of patients with neovascular age-related macular degeneration: results from the UK cohort of a five-country cross-sectional study. Br J Ophthalmol 91: 1303-1307.
16. Mißlbeck A (2007) Augenärzte gesucht. Augenspiegel 11: 15.
17. Neubauer A, Holz F, Sauer S et al (2010) Cost-effectiveness of ranibizumab for the treatment of neovascular age-related macular degeneration in Germany: model analysis from the perspective of Germany's statutory health insurance system. Clin Ther 32: 1343-1356.
18. Prautzsch J (2010) AMD-Therapie unter "real life"-Bedingungen. Z Prakt Augenheilkd 31: 1-4.
19. Przywara B (2010) Projecting future health care expenditure at European level: drivers, methodology and main results. European Commission Economic papers 417.
20. Raftery J, Clegg A, Jones J et al (2007) Ranibizumab (Lucentis) versus bevacizumab (Avastin): modelling cost effectiveness. Br J Ophthalmol 91: 1244-1246.
21. Schrader WF (2006) Age-related macular degeneration: a socioeconomic time bomb in our aging society. Ophthalmologe 103: 742-748.
22. van Der Zee J, Kroneman MW (2007) Bismarck or Beveridge: a beauty contest between dinosaurs. BMC Health Serv Res 7: 94.